Cytological Biomarkers

Cytology have been act as a main tools utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides  to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression  and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

 

  • cytological carcinoma
  • Cytopathology marker

Related Conference of Cytological Biomarkers

February 05-06, 2026

11th World Conference on Breast and Cervical Cancer

Paris, France
February 19-20, 2026

7th Cancer Diagnostics & Treatment Conference

Miami, USA
February 19-20, 2026

8th International Conference on Women Oncology

Miami, USA
March 09-10, 2026

4th World Congress on Oral Cancer

Singapore City, Singapore
March 30-31, 2026

26th World Congress on Cancer and Diagnostics

London, UK
June 15-16, 2026

10th Global Meeting on Oncology and Radiology

Paris, France
June 22-23, 2026

16th World Congress on Breast Cancer

Dubai, UAE
June 23-24, 2026

27th World Congress on Cancer Summit

Paris, France
July 27-28, 2026

6th World Congress on Breast Cancer

Rome, Italy
September 28-29, 2026

36th Experts Meet On Cancer Research & Therapy

Aix-en-Provence, France

Cytological Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in